Endocrine Abstracts

Objectives: Lenvatinib treatment is responsible for several adverse events (AEs). Hypocalcemia has been described in the registration study in 7% of patients, being of grade ≥3 in 2.7% of cases. No real-life studies are available, and the actual impact of this AE during Lenvatinib treatment is still unknown. Aim of our study is to evaluate the frequency of hypocalcemia in our series of patients treated with Lenvatinib and the possible predictors of this side effect.<...

In the last decades, multi-tyrosine-kinase inhibitors (mTKI) have emerged as an effective treatment for radioiodine refractory differentiated thyroid cancer. Due to their pleiotropic mechanism of action, these drugs may cause different side effects. Hypocalcaemia has been reported in up to 35% of patients treated with mTKI, but up to date little is known about its pathophysiology and relevance. We report the case of a 78 years old woman operated on for a papillary thyroid canc...

Objectives: The worldwide incidence of thyroid cancer (TC) is increasing at an alarming rate in the last decades and environmental pollution has been suggested to be involved in this rise. Some environmental pollutants, namely endocrine disruptive chemicals (EDCs), have been linked to endocrine system disruption, including thyroid dysfunction, and increased risk of cancer. Among EDCs, per- and polyfluoroalkyl substances (PFAS) are widely used in many industrial and consumer pr...

Background: Several adverse events are recorded during treatment with tyrosine-kinase inhibitors (TKIs). Hypocalcemia was reported during phase III clinical trials with both Lenvatinib and Vandetanib, but scanty data are available in a real-life setting. Aim of our study was to evaluate hypocalcemia occurrence and its characteristics in a cohort of patients treated with these drugs for advanced thyroid cancer. Moreover, in patients treated with Lenvatinib, we examined a possib...

Selpercatinib is a specific RET inhibitor, highly effective in the treatment of advanced RET-mutant medullary thyroid carcinoma (MTC). The consequences of selpercatinib administration in MTC patients who have not undergone thyroid surgery are still unknown. We report the case of an 84-year-old man undergoing investigations for worsening diarrhea and weight loss. Upon a neck ultrasound scan and blood exams that pointed out high levels of both calcitonin (CT, 20.583 ng/l) and ca...

Objectives: Recent evidence suggest that environmental pollution may be involved in the worldwide increase of thyroid cancer (TC) incidence occurred over the last few decades. Indeed, some environmental pollutants, namely endocrine disruptive chemicals (EDCs), have been linked to endocrine system disruption, including thyroid dysfunction, and increased risk of TC. Several EDCs are known to be Persistent Organic Pollutants (POPs) due to their long half-life in the environment, ...

Background: Hypertension (HTN) is the most frequent adverse event during treatment with Lenvatinib (LEN) for advanced Radioactive Iodine-Resistant Thyroid Cancer (RAI-R TC), but data on its best therapeutic management are limited.Objectives: To assess incidence, features and best management of LEN-related HTN in a consecutive single tertiary-care Centre.Methods: Evaluation included 29 patients treated with LEN, followed for a mean ...